




# PHARMACEUTICAL 2018

Vistagen Therapeutics Inc.  
Rank 315 of 342





# PHARMACEUTICAL 2018

Vistagen Therapeutics Inc.  
Rank 315 of 342



The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is -270%, being 316% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	3,378
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,368
Liabilities, Non-Current	1,729
Other Assets	48
Other Compr. Net Income	0
Other Expenses	7.0
Other Liabilities	0
Other Net Income	0
Other Revenues	1,250
Property and Equipment	286
Research and Development	5,204
Selling, General and Administrative Expense	6,295

Output Variable	Value in 1000 USD
Assets	3,712
Liabilities	3,096
Expenses	11,506
Revenues	1,250
Stockholders Equity	616
Net Income	-10,256
Comprehensive Net Income	-10,256
Economic Capital Ratio	-270%